Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 19, 2018
Previous Article Next Article

A cancer specific oxaliplatin-releasing Pt(iv)-prodrug

Author affiliations

Abstract

We prepared a Pt(IV)-prodrug, which under cancer specific conditions (elevated concentration of reactive oxygen species, ROS) releases a DNA-binding drug oxaliplatin as well as ROS-amplifying drugs p-quinone methide and N-alkylferrocenium. Due to the concerted action of these components, an excellent anticancer effect was achieved: IC50 = 0.4 ± 0.1 μM for human ovarian carcinoma A2780 cells. Importantly, the prodrug was found to be 45-fold less toxic to normal cells (HDFa).

Graphical abstract: A cancer specific oxaliplatin-releasing Pt(iv)-prodrug

Back to tab navigation

Supplementary files

Article information


Submitted
13 Apr 2018
Accepted
23 Apr 2018
First published
23 Apr 2018

Dalton Trans., 2018,47, 6679-6682
Article type
Communication

A cancer specific oxaliplatin-releasing Pt(IV)-prodrug

V. Reshetnikov, A. Arkhypov, P. R. Julakanti and A. Mokhir, Dalton Trans., 2018, 47, 6679
DOI: 10.1039/C8DT01458B

Social activity

Search articles by author

Spotlight

Advertisements